Oncolytic virus-induced cell death and immunity: A match made in heaven?

Journal of Leukocyte Biology

Volumn 102, Issue 3, 2017, Pages 631-643

  De Munck, Jolien ^a   Binks, Alex ^b   McNeish, Iain A ^b   Aerts, Joeri L ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cancer; Neoepitopes; T cells

Indexed keywords

DNX 2401; EVEROLIMUS; G 207; H 101; NTX 010; ONCOLYTIC VIRUS; ONCORINE; ONCOS 102; PELAREOREP; PEXASTIMOGENE DEVACIREPVEC; RIGVIR; TALIMOGENE LAHERPAREPVEC; UNCLASSIFIED DRUG;

CANCER IMMUNIZATION; CELL DEATH; CELL KILLING; CELLULAR IMMUNITY; HUMAN; MALIGNANT NEOPLASM; NONHUMAN; ONCOLYTIC VIROTHERAPY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR CELL; TUMOR IMMUNITY; ANIMAL; IMMUNOLOGY; NEOPLASMS; PROCEDURES;

ANIMALS; CELL DEATH; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 85028678410     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.5RU0117-040R     Document Type: Review

References (117)

1. Ehrlich, P. (1909) Ueber den jetzigen stand der karzinoforschung. Ned. Tijdschr. Geneeskd. 5, 273–290.
2. Burnet, F. M. (1970) The concept of immunological surveillance. Prog. Exp. Tumor Res. 13, 1–27.
3. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., Schreiber, R. D. (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991–998.
4. Kim, R., Emi, M., Tanabe, K. (2007) Cancer immunoediting from immune surveillance to immune escape. Immunology 121, 1–14.
5. Vogelstein, B. Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, Jr., L. A. Kinzler, K.W. (2013) Cancer genome landscapes. Science 339, 1546–1558.
6. Heemskerk, B., Kvistborg, P., Schumacher, T. N. M. (2013) The cancer antigenome. EMBO J. 32, 194–203.
7. Gajewski, T. F., Schreiber, H., Fu, Y.-X. (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14, 1014–1022.
8. De Gruijl, T. D., Janssen, A. B., van Beusechem, V. W. (2015) Arming oncolytic viruses to leverage antitumor immunity. Expert Opin. Biol. Ther. 15, 959–971.
9. Hanahan, D., Coussens, L. M. (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309–322.
10. Khalil, D. N., Smith, E. L., Brentjens, R. J., Wolchok, J. D. (2016) The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat. Rev. Clin. Oncol. 13, 273–290.
11. Brunet, J.-F., Denizot, F., Luciani, M.-F., Roux-Dosseto, M., Suzan, M., Mattei, M. G., Golstein, P. (1987) A new member of the immunoglobulin superfamily–CTLA-4. Nature 328, 267–270.
12. Ishida, Y., Agata, Y., Shibahara, K., Honjo, T. (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11, 3887–3895.
13. Monney, L., Sabatos, C. A., Gaglia, J. L., Ryu, A., Waldner, H., Chernova, T., Manning, S., Greenfield, E. A., Coyle, A. J., Sobel, R. A., Freeman, G. J., Kuchroo, V. K. (2002) Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415, 536–541.
14. Triebel, F., Jitsukawa, S., Baixeras, E., Roman-Roman, S., Genevee, C., Viegas-Pequignot, E., Hercend, T. (1990) LAG-3, a novel lymphocyte activation gene closely related to CD4. J. Exp. Med. 171, 1393–1405.
15. Wang, L., Rubinstein, R., Lines, J. L., Wasiuk, A., Ahonen, C., Guo, Y., Lu, L. F., Gondek, D., Wang, Y., Fava, R. A., Fiser, A., Almo, S., Noelle, R. J. (2011) VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J. Exp. Med. 208, 577–592.
16. Le Mercier, I., Lines, J. L., Noelle, R. J. (2015) Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators. Front. Immunol. 6, 418.
17. Hodi, F. S., O’Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., van den Eertwegh, A. J., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbé, C., Peschel, C., Quirt, I., Clark, J. I., Wolchok, J. D., Weber, J. S., Tian, J., Yellin, M. J., Nichol, G. M., Hoos, A., Urba, W. J. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723.
18. Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., Leming, P. D., Spigel, D. R., Antonia, S. J., Horn, L., Drake, C. G., Pardoll, D. M., Chen, L., Sharfman, W. H., Anders, R. A., Taube, J. M., McMiller, T. L., Xu, H., Korman, A. J., Jure-Kunkel, M., Agrawal, S., McDonald, D., Kollia, G. D., Gupta, A., Wigginton, J. M., Sznol, M. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454.
19. Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R. A., Reed, K., Burke, M. M., Caldwell, A., Kronenberg, S. A., Agunwamba, B. U., Zhang, X., Lowy, I., Inzunza, H. D., Feely, W., Horak, C. E., Hong, Q., Korman, A. J., Wigginton, J. M., Gupta, A., Sznol, M. (2013) Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122–133.
20. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., Ferrucci, P. F., Hill, A., Wagstaff, J., Carlino, M. S., Haanen, J. B., Maio, M., Marquez-Rodas, I., McArthur, G. A., Ascierto, P. A., Long, G. V., Callahan, M. K., Postow, M. A., Grossmann, K., Sznol, M., Dreno, B., Bastholt, L., Yang, A., Rollin, L. M., Horak, C., Hodi, F. S., Wolchok, J. D. (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34.
21. McDermott, D. F., Atkins, M. B. (2013) PD-1 as a potential target in cancer therapy. Cancer Med. 2, 662–673.
22. Zou, W., Chen, L. (2008) Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 8, 467–477.
23. Naidoo, J., Page, D. B., Wolchok, J. D. (2014) Immune modulation for cancer therapy. Br. J. Cancer 111, 2214–2219.
24. Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., Gilson, M. M., Wang, C., Selby, M., Taube, J. M., Anders, R., Chen, L., Korman, A. J., Pardoll, D. M., Lowy, I., Topalian, S. L. (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167–3175.
25. Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., Hollmann, T. J., Bruggeman, C., Kannan, K., Li, Y., Elipenahli, C., Liu, C., Harbison, C. T., Wang, L., Ribas, A., Wolchok, J. D., Chan, T. A. (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189–2199.
26. Rizvi, N. A. Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., Miller, M. L., Rekhtman, N., Moreira, A. L., Ibrahim, F., Bruggeman, C., Gasmi, B., Zappasodi, R., Maeda, Y., Sander, C., Garon, E. B., Merghoub, T., Wolchok, J. D., Schumacher, T. N., Chan, T. A. (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128.
27. Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W. J., Mulder, G. E., Toebes, M., Vesely, M. D., Lam, S. S., Korman, A. J., Allison, J. P., Freeman, G. J., Sharpe, A. H., Pearce, E. L., Schumacher, T. N., Aebersold, R., Rammensee, H. G., Melief, C. J., Mardis, E. R., Gillanders, W. E., Artyomov, M. N., Schreiber, R. D. (2014) Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577–581.
28. Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., Coutant, F., Métivier, D., Pichard, E., Aucouturier, P., Pierron, G., Garrido, C., Zitvogel, L., Kroemer, G. (2005) Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202, 1691–1701.
29. Hanahan, D., Weinberg, R. A. (2011) Hallmarks of cancer: the next generation. Cell 144, 646–674.
30. Kaczmarek, A., Vandenabeele, P., Krysko, D. V. (2013) Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity 38, 209–223.
31. Degterev, A., Huang, Z., Boyce, M., Li, Y., Jagtap, P., Mizushima, N., Cuny, G. D., Mitchison, T. J., Moskowitz, M. A., Yuan, J. (2005) Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat. Chem. Biol. 1, 112–119.
32. Holler, N., Zaru, R., Micheau, O., Thome, M., Attinger, A., Valitutti, S., Bodmer, J. L., Schneider, P., Seed, B., Tschopp, J. (2000) Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat. Immunol. 1, 489–495.
33. Pasparakis, M., Vandenabeele, P. (2015) Necroptosis and its role in inflammation. Nature 517, 311–320.
34. Pierdomenico, M., Negroni, A., Stronati, L., Vitali, R., Prete, E., Bertin, J., Gough, P. J., Aloi, M., Cucchiara, S. (2014) Necroptosis is active in children with inflammatory bowel disease and contributes to heighten intestinal inflammation. Am. J. Gastroenterol. 109, 279–287.
35. He, S., Wang, L., Miao, L., Wang, T., Du, F., Zhao, L., Wang, X. (2009) Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 137, 1100–1111.
36. Aaes, T. L., Kaczmarek, A., Delvaeye, T., De Craene, B., De Koker, S., Heyndrickx, L., Delrue, I., Taminau, J., Wiernicki, B., De Groote, P., Garg, A. D., Leybaert, L., Grooten, J., Bertrand, M. J., Agostinis, P., Berx, G., Declercq, W., Vandenabeele, P., Krysko, D. V. (2016) Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity. Cell Reports 15, 274–287.
37. Croker, B. A., O’Donnell, J. A., Gerlic, M. (2014) Pyroptotic death storms and cytopenia. Curr. Opin. Immunol. 26, 128–137.
38. Levine, B., Kroemer, G. (2008) Autophagy in the pathogenesis of disease. Cell 132, 27–42.
39. Liu, Y., Levine, B. (2015) Autosis and autophagic cell death: the dark side of autophagy. Cell Death Differ. 22, 367–376
40. Tanida, I., Ueno, T., Kominami, E. (2008) LC3 and autophagy. Methods Mol. Biol. 445, 77–88.
41. Kang, R., Zeh, H. J., Lotze, M. T., Tang, D. (2011) The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 18, 571–580.
42. Galluzzi, L., Vitale, I., Abrams, J. M., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., Dawson, T. M., Dawson, V. L., El-Deiry, W. S., Fulda, S., Gottlieb, E., Green, D. R., Hengartner, M. O., Kepp, O., Knight, R. A., Kumar, S., Lipton, S. A., Lu, X., Madeo, F., Malorni, W., Mehlen, P., Nuñez, G., Peter, M. E., Piacentini, M., Rubinsztein, D. C., Shi, Y., Simon, H. U., Vandenabeele, P., White, E., Yuan, J., Zhivotovsky, B., Melino, G., Kroemer, G. (2012) Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 19, 107–120.
43. Kroemer, G., Galluzzi, L., Kepp, O., Zitvogel, L. (2013) Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51–72.
44. Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., Rello-Varona, S., Tailler, M., Menger, L., Vacchelli, E., Galluzzi, L., Ghiringhelli, F., di Virgilio, F., Zitvogel, L., Kroemer, G. (2011) Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334, 1573–1577.
45. Russell, S. J., Peng, K.-W., Bell, J. C. (2012) Oncolytic virotherapy. Nat. Biotechnol. 30, 658–670.
46. Jeeninga, R. E., Jan, B., van der Linden, B., van den Berg, H., Berkhout, B. (2005) Construction of a minimal HIV-1 variant that selectively replicates in leukemic derived T-cell lines: towards a new virotherapy approach. Cancer Res. 65, 3347–3355.
47. Jeeninga, R. E., Jan, B., van den Berg, H., Berkhout, B. (2006) Construction of doxycyline-dependent mini-HIV-1 variants for the development of a virotherapy against leukemias. Retrovirology 3, 64.
48. Seymour, L. W., Fisher, K. D. (2016) Oncolytic viruses: finally delivering. Br. J. Cancer 114, 357–361.
49. Maclean, A. R., Ui-fareed, M., Robertson, L., Harland, J., Brown, S. M. (1991) Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17 + between immediate early gene 1 and the ‘a’ sequence. J. Gen. Virol. 72, 631–639.
50. Mossman, K. L., Smiley, J. R. (2002) Herpes simplex virus ICP0 and ICP34.5 counteract distinct interferon-induced barriers to virus replication. J. Virol. 76, 1995–1998.
51. Schneider, U., Bullough, F., Vongpunsawad, S., Russell, S. J., Cattaneo, R. (2000) Recombinant measles viruses efficiently entering cells through targeted receptors. J. Virol. 74, 9928–9936.
52. Tseng, A. W. S., Chen, C., Breslin, M. B., Lan, M. S. (2016) Tumor-specific promoter-driven adenoviral therapy for insulinoma. Cell Oncol. (Dordr.) 39, 279–286.
53. Yang, Y.-F., Xue, S. Y., Lu, Z. Z., Xiao, F. J., Yin, Y., Zhang, Q. W., Wu, C. T., Wang, H., Wang, L. S. (2014) Antitumor effects of oncolytic adenovirus armed with PSA-IZ-CD40L fusion gene against prostate cancer. Gene Ther. 21, 723–731.
54. Delwar, Z. M., Liu, G., Kuo, Y., Lee, C., Bu, L., Rennie, P. S., Jia, W. W. (2016) Tumour-specific triple-regulated oncolytic herpes virus to target glioma. Oncotarget 7, 28658–28669.
55. Chumakov, P. M., Morozova, V. V., Babkin, I. V., Baĭkov, I. K., Netesov, S. V., Tikunova, N. V. (2012) Oncolytic enteroviruses. Mol. Biol. 46, 712–725.
56. Garber, K. (2006) China approves world’s first oncolytic virus therapy for cancer treatment. J. Natl. Cancer Inst. 98, 298–300.
57. Debbas, M., White, E. (1993) Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev. 7, 546–554.
58. Nemunaitis, J., Ganly, I., Khuri, F., Arseneau, J., Kuhn, J., McCarty, T., Landers, S., Maples, P., Romel, L., Randlev, B., Reid, T., Kaye, S., Kirn, D. (2000) Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 60, 6359–6366.
59. Harada, J. N., Berk, A. J. (1999) p53-independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J. Virol. 73, 5333–5344.
60. O’Shea, C. C., Johnson, L., Bagus, B., Choi, S., Nicholas, C., Shen, A., Boyle, L., Pandey, K., Soria, C., Kunich, J., Shen, Y., Habets, G., Ginzinger, D., McCormick, F. (2004) Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6, 611–623.
61. Xia, Z.-J., Chang J. H., Zhang L., Jiang W. Q., Guan Z. Z, Liu J. W., Zhang Y., Hu X. H., Wu G. H., Wang H. Q., Chen Z. C., Chen J. C., Zhou Q. H., Lu J. W., Fan Q. X., Huang J. J., Zheng X. (2004) Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng 23, 1666–1670.
62. Hu, J. C. C., Coffin, R. S., Davis, C. J., Graham, N. J., Groves, N., Guest, P. J., Harrington, K. J., James, N. D., Love, C. A., McNeish, I., Medley, L. C., Michael, A., Nutting, C. M., Pandha, H. S., Shorrock, C. A., Simpson, J., Steiner, J., Steven, N. M., Wright, D., Coombes, R. C. (2006) A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin. Cancer Res. 12, 6737–6747.
63. Rampling, R., Cruickshank, G., Papanastassiou, V., Nicoll, J., Hadley, D., Brennan, D., Petty, R., MacLean, A., Harland, J., McKie, E., Mabbs, R., Brown, M. (2000) Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 7, 859–866.
64. Markert, J. M., Liechty, P. G., Wang, W., Gaston, S., Braz, E., Karrasch, M., Nabors, L. B., Markiewicz, M., Lakeman, A. D., Palmer, C. A., Parker, J. N., Whitley, R. J., Gillespie, G. Y. (2009) Phase Ib trial of mutant herpes simplex virus G207 inoculated pre- and post-tumor resection for recurrent GBM. Mol. Ther. 17, 199–207.
65. MacKie, R. M., Stewart, B., Brown, S. M. (2001) Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 357, 525–526.
66. Mohr, I., Gluzman, Y. (1996) A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. EMBO J. 15, 4759–4766.
67. Liu, B. L., Robinson, M., Han, Z. Q., Branston, R. H., English, C., Reay, P., McGrath, Y., Thomas, S. K., Thornton, M., Bullock, P., Love, C. A., Coffin, R. S. (2003) ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 10, 292–303.
68. Toda, M., Martuza, R. L., Rabkin, S. D. (2000) Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Mol. Ther. 2, 324–329.
69. Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., Milhem, M., Cranmer, L., Curti, B., Lewis, K., Ross, M., Guthrie, T., Linette, G. P., Daniels, G. A., Harrington, K., Middleton, M. R., Miller, W. H., Jr., Zager, J. S., Ye, Y., Yao, B., Li, A., Doleman, S., VanderWalde, A., Gansert, J., Coffin, R. S. (2015) Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780–2788.
70. Gong, J., Sachdev, E., Mita, A. C., Mita, M. M. (2016) Clinical development of reovirus for cancer therapy: an oncolytic virus with immune-mediated antitumor activity. World J. Methodol. 6, 25–42.
71. Hashiro, G., Loh, P. C., Yau, J. T. (1977) The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch. Virol. 54, 307–315.
72. Duncan, M. R., Stanish, S. M., Cox, D. C. (1978) Differential sensitivity of normal and transformed human cells to reovirus infection. J. Virol. 28, 444–449.
73. Kim, J. H., Oh, J. Y., Park, B. H., Lee, D. E., Kim, J. S., Park, H. E., Roh, M. S., Je, J. E., Yoon, J. H., Thorne, S. H., Kirn, D., Hwang, T. H. (2006) Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol. Ther. 14, 361–370.
74. Heo, J., Reid, T., Ruo, L., Breitbach, C. J., Rose, S., Bloomston, M., Cho, M., Lim, H. Y., Chung, H. C., Kim, C. W., Burke, J., Lencioni, R., Hickman, T., Moon, A., Lee, Y. S., Kim, M. K., Daneshmand, M., Dubois, K., Longpre, L., Ngo, M., Rooney, C., Bell, J. C., Rhee, B. G., Patt, R., Hwang, T. H., Kirn, D. H. (2013) Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med. 19, 329–336.
75. Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., Martuza, R. L. (1995) Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1, 938–943.
76. Preston, V. G., Palfreyman, J. W., Dutia, B. M. (1984) Identification of a herpes simplex virus type 1 polypeptide which is a component of the virus-induced ribonucleotide reductase J. Gen. Virol. 65, 1457–1466.
77. Markert, J. M., Razdan, S. N., Kuo, H. C., Cantor, A., Knoll, A., Karrasch, M., Nabors, L. B., Markiewicz, M., Agee, B. S., Coleman, J. M., Lakeman, A. D., Palmer, C. A., Parker, J. N., Whitley, R. J., Weichselbaum, R. R., Fiveash, J. B., Gillespie, G. Y. (2014) A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol. Ther. 22, 1048–1055.
78. Bilsland, A. E., Spiliopoulou, P., Evans, T. R. J. (2016) Virotherapy: cancer gene therapy at last? F1000 Res. 5, 2105.
79. Kuhn, I., Harden, P., Bauzon, M., Chartier, C., Nye, J., Thorne, S., Reid, T., Ni, S., Lieber, A., Fisher, K., Seymour, L., Rubanyi, G. M., Harkins, R. N., Hermiston, T. W. (2008) Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One 3, e2409.
80. Miyamoto, S., Inoue, H., Nakamura, T., Yamada, M., Sakamoto, C., Urata, Y., Okazaki, T., Marumoto, T., Takahashi, A., Takayama, K., Nakanishi, Y., Shimizu, H., Tani, K. (2012) Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res. 72, 2609–2621.
81. Meshii, N., Takahashi, G., Okunaga, S., Hamada, M., Iwai, S., Takasu, A., Ogawa, Y., Yura, Y. (2013) Enhancement of systemic tumor immunity for squamous cell carcinoma cells by an oncolytic herpes simplex virus. Cancer Gene Ther. 20, 493–498.
82. Guo, Z. S., Liu, Z., Bartlett, D. L. (2014) Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity. Front. Oncol. 4, 74.
83. Koks, C. A., Garg, A. D., Ehrhardt, M., Riva, M., Vandenberk, L., Boon, L., De Vleeschouwer, S., Agostinis, P., Graf, N., Van Gool, S. W. (2015) Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death. Int. J. Cancer 136, E313–E325.
84. Workenhe, S. T., Simmons, G., Pol, J. G., Lichty, B. D., Halford, W. P., Mossman, K. L. (2014) Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy. Mol. Ther. 22, 123–131.
85. Ito, H., Aoki, H., Kühnel, F., Kondo, Y., Kubicka, S., Wirth, T., Iwado, E., Iwamaru, A., Fujiwara, K., Hess, K. R., Lang, F. F., Sawaya, R., Kondo, S. (2006) Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J. Natl. Cancer Inst. 98, 625–636.
86. Rodriguez-Rocha, H., Gomez-Gutierrez, J. G., Garcia-Garcia, A., Rao, X. M., Chen, L., McMasters, K. M., Zhou, H. S. (2011) Adenoviruses induce autophagy to promote virus replication and oncolysis. Virology 416, 9–15.
87. Baird, S. K., Aerts, J. L., Eddaoudi, A., Lockley, M., Lemoine, N. R., McNeish, I. A. (2008) Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer. Oncogene 27, 3081–3090.
88. Klein, S. R., Jiang, H., Hossain, M. B., Fan, X., Gumin, J., Dong, A., Alonso, M. M., Gomez-Manzano, C., Fueyo, J. (2016) Critical role of autophagy in the processing of adenovirus capsid-incorporated cancer-specific antigens. PLoS One 11, e0153814.
89. Lelli, J. L., Jr., Becks, L. L., Dabrowska, M. I., Hinshaw, D. B. (1998) ATP converts necrosis to apoptosis in oxidant-injured endothelial cells. Free Radic. Biol. Med. 25, 694–702.
90. Diaconu, I., Cerullo, V., Hirvinen, M. L., Escutenaire, S., Ugolini, M., Pesonen, S. K., Bramante, S., Parviainen, S., Kanerva, A., Loskog, A. S., Eliopoulos, A. G., Pesonen, S., Hemminki, A. (2012) Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res. 72, 2327–2338.
91. Perkins, D., Pereira, E. F. R., Aurelian, L. (2003) The herpes simplex virus type 2 R1 protein kinase (ICP10 PK) functions as a dominant regulator of apoptosis in hippocampal neurons involving activation of the ERK survival pathway and upregulation of the antiapoptotic protein Bag-1. J. Virol. 77, 1292–1305.
92. Wales, S. Q., Laing, J. M., Chen, L., Aurelian, L. (2008) ICP10PK inhibits calpain-dependent release of apoptosis-inducing factor and programmed cell death in response to the toxin MPP+. Gene Ther. 15, 1397–1409.
93. Colunga, A. G., Laing, J. M., Aurelian, L. (2010) The HSV-2 mutant DeltaPK induces melanoma oncolysis through nonredundant death programs and associated with autophagy and pyroptosis proteins. Gene Ther. 17, 315–327.
94. Cabon, L., Galán-Malo, P., Bouharrour, A., Delavallée, L., Brunelle-Navas, M. N., Lorenzo, H. K., Gross, A., Susin, S. A. (2012) BID regulates AIF-mediated caspase-independent necroptosis by promoting BAX activation. Cell Death Differ. 19, 245–256.
95. Li, B., Smith, C. C., Laing, J. M., Gober, M. D., Liu, L., Aurelian, L. (2007) Overload of the heat-shock protein H11/HspB8 triggers melanoma cell apoptosis through activation of transforming growth factor-beta-activated kinase 1. Oncogene 26, 3521–3531.
96. Takasu, A., Masui, A., Hamada, M., Imai, T., Iwai, S., Yura, Y. (2016) Immunogenic cell death by oncolytic herpes simplex virus type 1 in squamous cell carcinoma cells. Cancer Gene Ther. 23, 107–113.
97. Takaoka, H., Takahashi, G., Ogawa, F., Imai, T., Iwai, S., Yura, Y. (2011) A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma. Virol. J. 8, 294.
98. Donnelly, O. G., Errington-Mais, F., Steele, L., Hadac, E., Jennings, V., Scott, K., Peach, H., Phillips, R. M., Bond, J., Pandha, H., Harrington, K., Vile, R., Russell, S., Selby, P., Melcher, A. A. (2013) Measles virus causes immunogenic cell death in human melanoma. Gene Ther. 20, 7–15.
99. Meiffren, G., Joubert, P. E., Grégoire, I. P., Codogno, P., Rabourdin-Combe, C., Faure, M. (2010) Pathogen recognition by the cell surface receptor CD46 induces autophagy. Autophagy 6, 299–300.
100. Fournier, P., Schirrmacher, V. (2013) Oncolytic Newcastle disease virus as cutting edge between tumor and host. Biology (Basel) 2, 936–975.
101. Angelova, A. L., Grekova, S. P., Heller, A., Kuhlmann, O., Soyka, E., Giese, T., Aprahamian, M., Bour, G., Rüffer, S., Cziepluch, C., Daeffler, L., Rommelaere, J., Werner, J., Raykov, Z., Giese, N. A. (2014) Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. J. Virol. 88, 5263–5276.
102. Whilding, L. M., Archibald, K. M., Kulbe, H., Balkwill, F. R., Öberg, D., McNeish, I. A. (2013) Vaccinia virus induces programmed necrosis in ovarian cancer cells. Mol. Ther. 21, 2074–2086.
103. Moon, K. B., Turner, P. C., Moyer, R. W. (1999) SPI-1-dependent host range of rabbitpox virus and complex formation with cathepsin G is associated with serpin motifs. J. Virol. 73, 8999–9010.
104. Kettle, S., Alcamí, A., Khanna, A., Ehret, R., Jassoy, C., Smith, G. L. (1997) Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1beta-converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1beta-induced fever. J. Gen. Virol. 78, 677–685.
105. Guo, Z. S., Naik, A., O’Malley, M. E., Popovic, P., Demarco, R., Hu, Y., Yin, X., Yang, S., Zeh, H. J., Moss, B., Lotze, M. T., Bartlett, D. L. (2005) The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res. 65, 9991–9998.
106. Simpson, G. R., Relph, K., Harrington, K., Melcher, A., Pandha, H. (2016) Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances. Oncolytic Virother. 5, 1–13.
107. Dunn, C. J., Goa, K. L. (1996) Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia. Drugs Aging 9, 122–147.
108. Workenhe, S. T., Pol, J. G., Lichty, B. D., Cummings, D. T., Mossman, K. L. (2013) Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy. Cancer Immunol. Res. 1, 309–319.
109. Siurala, M., Bramante, S., Vassilev, L., Hirvinen, M., Parviainen, S., Tähtinen, S., Guse, K., Cerullo, V., Kanerva, A., Kipar, A., Vähä-Koskela, M., Hemminki, A. (2015) Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma. Int. J. Cancer 136, 945–954.
110. Granata, S., Dalla Gassa, A., Carraro, A., Brunelli, M., Stallone, G., Lupo, A., Zaza, G. (2016) Sirolimus and everolimus pathway: reviewing candidate genes influencing their intracellular effects. Int. J. Mol. Sci. 17, 735.
111. Alonso, M. M., Jiang, H., Yokoyama, T., Xu, J., Bekele, N. B., Lang, F. F., Kondo, S., Gomez-Manzano, C., Fueyo, J. (2008) Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol. Ther. 16, 487–493.
112. Mizushima, N., Yamamoto, A., Hatano, M., Kobayashi, Y., Kabeya, Y., Suzuki, K., Tokuhisa, T., Ohsumi, Y., Yoshimori, T. (2001) Dissection of autophagosome formation using Apg5-deficient mouse embryonic stem cells. J. Cell Biol. 152, 657–668.
113. Liikanen, I., Ahtiainen, L., Hirvinen, M. L., Bramante, S., Cerullo, V., Nokisalmi, P., Hemminki, O., Diaconu, I., Pesonen, S., Koski, A., Kangasniemi, L., Pesonen, S. K., Oksanen, M., Laasonen, L., Partanen, K., Joensuu, T., Zhao, F., Kanerva, A., Hemminki, A. (2013) Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol. Ther. 21, 1212–1223.
114. Kanzawa, T., Germano, I. M., Komata, T., Ito, H., Kondo, Y., Kondo, S. (2004) Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ. 11, 448–457.
115. Chan, F. K.-M., Luz, N. F., Moriwaki, K. (2015) Programmed necrosis in the cross talk of cell death and inflammation. Annu. Rev. Immunol. 33, 79–106.
116. Lin, C., Zhang, J. (2017) Inflammasomes in inflammation-induced cancer. Front. Immunol. 8, 271.
117. Marnett, L. J. (2000) Oxyradicals and DNA damage. Carcinogenesis 21, 361–370.